0001209191-23-010735.txt : 20230217
0001209191-23-010735.hdr.sgml : 20230217
20230217170126
ACCESSION NUMBER: 0001209191-23-010735
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230215
FILED AS OF DATE: 20230217
DATE AS OF CHANGE: 20230217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Colgan Erin
CENTRAL INDEX KEY: 0001843563
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39980
FILM NUMBER: 23643677
MAIL ADDRESS:
STREET 1: C/O SENSEI BIOTHERAPEUTCS, INC.
STREET 2: 1405 RESEARCH BLVD., STE. 125
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001829802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 620 PROFESSIONAL DRIVE
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: (240) 243-8000
MAIL ADDRESS:
STREET 1: 620 PROFESSIONAL DRIVE
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-15
0
0001829802
Sensei Biotherapeutics, Inc.
SNSE
0001843563
Colgan Erin
C/O SENSEI BIOTHERAPEUTICS, INC.
451 D STREET, SUITE 710
BOSTON
MA
02210
0
1
0
0
Chief Financial Officer
Common Stock
2023-02-15
4
A
0
30046
0.00
A
51732
D
Common Stock
2023-02-15
4
A
0
21300
0.00
A
73032
D
Stock Option (Right to Buy)
1.43
2023-02-15
4
A
0
90000
0.00
A
2033-02-14
Common Stock
90000
90000
D
These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.
These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.
The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
/s/ Mark Ballantyne, Attorney-in-Fact
2023-02-17